Twist Bioscience closed fiscal 2026 with faster growth and a stronger operating profile. Revenue reached $459.4 million, up from $376.6 million in fiscal 2025, while gross margin reached 52.4%. Fourth-quarter revenue was $126.6 million, fourth-quarter gross margin was 53.1%, and quarterly adjusted EBITDA was positive at $2.2 million. Those results improved the operating evidence without settling how durable the progress will be.
The company also reported broader commercial scale, with approximately 4,100 customers and more than 1.3 million genes shipped during fiscal 2026. Together, the customer and shipment figures show that the growth story rests on a broader commercial base. At the same time, the full-year GAAP net loss was $130.2 million. That contrast matters because a positive quarterly adjusted EBITDA result is not the same as annual GAAP profitability or sustained cash generation.
Management's fiscal 2027 outlook points to continued revenue growth, a gross margin near the fiscal 2026 level, and positive adjusted EBITDA. The plan also assumes a substantial contribution from AI drug discovery and includes significant capital spending. Those assumptions make demand quality, capacity discipline, and the conversion of growth into cash important issues for the coming year.
The market context was still incomplete when the premium analysis was finished. Twist released fiscal 2026 results on November 12, but the first regular session after the release was still in progress. The analysis therefore kept its market-structure observations anchored to the completed November 11 session rather than treating a partial trading day as a finished verdict.
The full Twist Bioscience premium review examines the operating evidence, outlook assumptions, financial risks, and valuation framework in greater depth. This public note is a concise companion and does not reproduce the member analysis.
Market analysis, not personalized investment advice.